SLR-108 PET imaging study for metastatic solid tumors
Part of Cancer clinical trials.
This trial uses a special imaging agent called SLR-108 to take detailed PET scans of your cancer. It aims to see if this scan can help doctors better understand metastatic solid tumors that have grown after previous treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed solid tumor that has spread to other parts of the body and has grown despite previous treatment.
- You have at least one measurable tumor outside of any previous radiation area.
- You have had all prior cancer treatments stopped for at least 1 week before starting the study drug.
- You are willing to provide a fresh or stored tumor tissue sample.
- Your overall health, including blood counts, liver and kidney function, is adequate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 1 trial tests a new drug called SLV-324 for people with solid tumors that have spread and are no longer responding to standard treatments. The goal is to see if the drug is safe and works against the cancer.
This trial tests a new drug called SLV-154 for people whose advanced cancer has not responded to standard treatments. The goal is to see if SLV-154 can shrink tumors or slow cancer growth.
This early (Phase 1) study uses a special PET scan to measure how your immune system responds after stereotactic body radiation therapy (SBRT). The goal is to see whether the scan result can serve as a marker of immune response, which may help future treatment planning.
This study uses a special PET imaging scan to help doctors see how well pembrolizumab (an immunotherapy drug) is working against advanced non-small cell lung cancer. You'll receive the scan along with your regular pembrolizumab treatment and possible radiation therapy to help measure treatment response.
This trial uses a special PET scan (POSLUMA) before and after radiation to see if it helps treat prostate cancer that has spread to a few spots outside the pelvis. It's for men whose cancer still responds to hormone therapy and who have not had widespread spread.
This trial tests a new type of PET scan (a special imaging test) called 89Zr-s-C1 to help detect and monitor solid tumors like melanoma, gastric cancer, or colorectal cancer. The scan may help doctors see tumors more clearly and track whether treatment is working.
Hear when a new Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.